TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05630872
Drug: 2HPZM
Normalized name: Isoniazid, Pyrazinamide, Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen
Study: NCT05630872
Drug: 2HPM
Normalized name: Hydroxyproprylmethylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rifapentine-moxifloxacin plus isoniazid regimen
Study: NCT05413902
Drug: Toradol
Normalized name: Toradol
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study: NCT05413902
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provide the standard postoperative morphine dose for pain management as part of the traditional opioid-based pain management regime.
Study: NCT05413902
Drug: Orphenadrine
Normalized name: Orphenadrine
DrugBank: Orphenadrine (DB01173)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study: NCT05413902
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study: NCT06514651
Drug: MAQ-001
Normalized name: OCTINOXATE 0.1 g in 1 g TOPICAL CREAM [Maquillaje Liquido Maxima Cobertura]
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade
Study: NCT06514651
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
Study: NCT06577025
Drug: Cilta-cel
Normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilta-cel infusion will be administered intravenously.
Study: NCT06577025
Drug: Talquetamab
Normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talquetamab will be administered subcutaneously.
Study: NCT06577025
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
Study: NCT05413902
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study: NCT05413902
Drug: Xylocaine Injectable Solution
Normalized name: lidocaine Injection [Xylocaine]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study: NCT05413902
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Provide this drug as part of a multimodal pharmacologic regimen for pain management including multiple drugs mentioned in the group description.
Study: NCT06577025
Drug: Teclistamab
Normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teclistamab will be administered subcutaneously.
Study: NCT06577025
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib will be administered subcutaneously as a part of induction.
Study: NCT06398080
Drug: aflibercept 8 mg
Normalized name: aflibercept 8 MG in 0.07 ML Injection
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.
Study: NCT06577025
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered orally as a part of induction.
Study: NCT06577025
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be administered orally as a part of induction.
Study: NCT06577025
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be administered intravenously as a part of conditioning regimen.
Study: NCT06426043
Drug: Lusutrombopag
Normalized name: Lusutrombopag
DrugBank: Lusutrombopag (DB13125)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administer lusutrombopag at 3mg/qd orally for 12 weeks (lusutrombopag starting dose is 3mg, once daily. After 2 weeks of continuous administration, the dose can be increased by 3mg every 2 weeks based on the platelet count and safety of the subject. The dose can be gradually increased to 9mg/d over a total of 12 weeks). The course should be at least 3 months. When the platelet increase is \<20×109/L, the daily dose can be increased by 3mg up to a maximum of 9mg/day; when the platelet increase is ≥50×10\^9/L and ≤200×10\^9/L, the dose can be maintained; when the platelet count is ≥200×10\^9/L and ≤400×10\^9/L, the daily dose can be reduced by 3mg; when the platelet count is \>400×10\^9/L, the drug can be suspended and resumed when the platelet count decreases to \<200×10\^9/L, with the daily dose reduced by 3mg. In this case, if the lowest dose of 3mg/day is used, the drug can be suspended. Responders continue treatment until 6 months.
Study: NCT06282445
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This product is administered by intravenously guttae. The recommended dose of subcutaneous injection is 1200mg, administered every 3 Weeks (Q3W).
Study: NCT06282445
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2, ivgtt, d1, Q3W
Study: NCT06282445
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5mg/kg，ivgtt, d1, Q3W
Study: NCT05058651
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05058651
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05058651
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06365853
Drug: Mirvetuximab Soravtansine
Normalized name: MIRVETUXIMAB SORAVTANSINE
DrugBank: Mirvetuximab soravtansine (DB12489)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirvetuximab soravtansine is an antibody drug conjugate designed to target folate receptor α (FRα). It consists of the humanized anti-FRα monoclonal antibody (mAb) M9346A attached via a cleavable disulfide linker to the cytotoxic maytansinoid, DM4.
Study: NCT06365853
Drug: Lubricating Eye Drops
Normalized name: Ultra Lubricating Eye Drops
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubricating artificial tears should be administered at least 15 minutes after corticosteroid or brimonidine eye drop administration.
Study: NCT06365853
Drug: Brimonidine tartrate ophthalmic solution eye drops
Normalized name: brimonidine tartrate Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Self-administration of brimonidine tartrate ophthalmic solution eye drops as prescribed by the treating physician.
Study: NCT06346522
Drug: Gabapentin (Gaptin ®) 400mg oral capsule once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the patient will regain feeding, the patients will take with sips of water Gabapentin (Gaptin ®) 400mg oral capsule once in the first 24 hour after icu admission
Study: NCT06346522
Drug: Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule
Normalized name: trospium chloride 60 MG
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the patient will regain feeding, the patients will take with sips of water Trospium chloride slow release (Trospikan ® SR) 60mg oral capsule once in the first 24 hour after icu admission
Study: NCT06064097
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06064097
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06216301
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Study: NCT06216301
Drug: Platinum based chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer
Study: NCT06207305
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by PO
Study: NCT06207305
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06207305
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06207305
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT06434363
Drug: Tafasitamab
Normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by vein (IV)
Study: NCT06434363
Drug: Fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by vein (IV)
Study: NCT06592924
Drug: Abiraterone
Normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assigned prior to enrollment
Study: NCT06592924
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Assigned prior to enrollment
Study: NCT06592924
Drug: Apalutamide
Normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Assigned prior to enrollment
Study: NCT06592924
Drug: Darolutamide (BAY 1841788)
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Assigned prior to enrollment
Study: NCT06592924
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Assigned at enrollment
Study: NCT05308940
Drug: TB001
Normalized name: CTB001
DrugBank: CTB001 (DB18316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-daily subcutaneous injection, on Day 1 in SAD stage
Study: NCT05308940
Drug: TB001
Normalized name: CTB001
DrugBank: CTB001 (DB18316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once-daily subcutaneous injection, on Days 1-7 in MAD stage
Study: NCT05364021
Drug: LP352
Normalized name: Linzagolix
DrugBank: Linzagolix (DB17083)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP352 administered three times daily, orally or through G-tube
Study: NCT05088655
Drug: Hetrombopag Olamine Tablet
Normalized name: Eltrombopag Olamine
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag Olamine Tablet (T: test formulation) Hetrombopag Olamine Tablet (R: reference formulation)
Study: NCT04768907
Drug: MaaT013
Normalized name: MaaT013
DrugBank: MaaT013 (DB18648)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06575933
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration
Study: NCT06575933
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00002243
Drug: Calanolide A
Normalized name: Calanolide A
DrugBank: Calanolide A (DB04886)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04842825
Drug: Er Zhi Wan combined with Si Wu Tang
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The TCM medicines used will be Radix et Rhizoma Ligustrum 15 g, Radix Morindae Sinensis 12 g, Fructus Lycii 15 g, Semen Cuscutae 20 g, Radix Rehmanniae 20 g, Radix Angelicae Sinensis 10 g, Radix Paeoniae Alba 12 g, Radix Yam 20 g. The hospital will be responsible for the decoction of 200 mL per dose, 1 dose per day, divided into 2 doses in the morning and in the evening, for 10-15 days. According to follicular development and endometrial growth monitored by ultrasound, the herbs will be changed to Curculus 10 g, Xianling spleen 15 g, Morinda officinalis 15 g, Cuscutae 20 g, Amethyst 15 g, Rehmannia 20 g, Angelica 15 g, Chuanxiong 10 g，which will be taken for 10-15days.~After ET, the treatment group will continue to take Chinese herbal medicine, changing to Cuscuta 15 g, Sambucus 15 g, Chuan Guan Gong 10 g, Agaricus 9 g, Shu Di 15 g, Angelica 10 g, Bai Shao 12 g for 14 days
Study: NCT04842825
Drug: Recombinant Human Follitropin Alfa 、Fructose 、Tetyacycline Hydrochloride Capsules、Cetrorelix Acetate Powder
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group will be treated with conventional Western medicine（The specific drug dose is determined according to the individual level of patients）
Study: NCT04809103
Drug: cis-diamminedichloroplatinum
Normalized name: CIS-DIAMMINEDICHLOROPLATINUM
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin delivered bronchoscopically at the time of diagnosis of NSCLC
Study: NCT05918640
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lurbinectedin will be administered on a Day 1, Day 4 schedule every 21 days. Doses will be determined in the phase 1 portion of the trial.
Study: NCT06344104
Drug: Baxdrostat
Normalized name: Baxdrostat
DrugBank: Baxdrostat (DB19090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baxdrostat tablet administered orally, once daily (QD). Unit dose strength:~* 1 mg per tablet for 1mg baxdrostat Arm~* 2 mg per tablet for 2mg baxdrostat Arm
Study: NCT04790136
Drug: GLA-015
Normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration followed by PK blood sampling
Study: NCT04790136
Drug: DAC C-052 Cannabidiol / NRF 22.10 Oily cannabidiol solution 100 mg/ml
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: administration followed by PK blood sampling
Study: NCT05377788
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of EGFR T790M mutant-positive local progressive or metastatic non-small cell lung cancer patients who have previously been treated with EGFR
Study: NCT06369155
Drug: Azenosertib
Normalized name: Azenosertib
DrugBank: Azenosertib (DB18028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wee1 inhibitor, 25mg and 100mg tablets, taken orally per protocol.
Study: NCT04817826
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).
Study: NCT04817826
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tremelimumab 300 mg single administration (day 1)
Study: NCT06551272
Drug: EXL01
Normalized name: Elexacaftor
DrugBank: Elexacaftor (DB15444)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EXL01 contains an unmodified single strain of F. prausnitzii
Study: NCT05753189
Drug: Aceclidine+Brimonidine combination ophthalmic solution
Normalized name: brimonidine Ophthalmic Solution
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination ophthalmic solution of Aceclidine and Brimonidine
Study: NCT05753189
Drug: Aceclidine Ophthalmic Solution
Normalized name: Aceclidine
DrugBank: Aceclidine (DB13262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceclidine
Study: NCT05817708
Drug: CX-4945
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: CX-4945~Silmitasertib, orally, once or twice daily for 5 days.~Other Name: Silmitasertib
Study: NCT05194358
Drug: Stabilized Isoamyl Nitrite (SIAN)
Normalized name: isoamyl cinnamate
DrugBank: Amyl Nitrite (DB01612)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SIAN is comprised of isoamyl nitrite (IAN) stabilized with 4% by weight epoxidized linseed oil (ELSO) and administered by intranasal (IN) delivery as a nasal spray.~A syringe-based spray device will be used to administer the SIAN product. This syringe-based spray device, consists of a Hamilton type syringe connected to a tip that functions as an atomizer, to provide an optimal spray plume for nasal absorption while minimizing exposure to lungs.
Study: NCT06223516
Drug: Subcutaneous (SC) ABBV-383
Normalized name: Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383
DrugBank: TNB-383B (DB17268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC Injection
Study: NCT06223516
Drug: Intravenous (IV) ABBV-383
Normalized name: Anti-BCMA/Anti-CD3 T-cell Engaging Bispecific Antibody ABBV-383
DrugBank: TNB-383B (DB17268)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT06346197
Drug: Balstilimab
Normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balstilimab: 240mg, IV, Q2W, until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
Study: NCT06346197
Drug: Botensilimab
Normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botensilimab: 75mg, IV for up to 4 doses, Q6W until disease progression, unacceptable toxicity, patient or investigator decision or up to 2 years.
Study: NCT06346197
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
Study: NCT05056194
Drug: Valiloxybate
Normalized name: Valiloxybate
DrugBank: Valiloxibic acid (DB16937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XW10172 MR Granules for Oral Suspension
Study: NCT05308654
Drug: ABBV-453
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral; Tablet
Study: NCT05308654
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Tablet
Study: NCT05308654
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous Injection
Study: NCT05308654
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Capsule
Study: NCT06269146
Drug: Pramipexole Pill
Normalized name: pramipexole Pill
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.
Study: NCT05700721
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by PO
Study: NCT05700721
Drug: Dostarlimab
Normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by IV (vein)
Study: NCT05488847
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: preoperative and discharge pain medication given to all patients
Study: NCT05488847
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: preoperative pain medication given to all patients
Study: NCT05488847
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative and discharge pain medication given to all patients
Study: NCT05488847
Drug: Tizanidine
Normalized name: Tizanidine
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discharge pain medication given to all patients
Study: NCT05488847
Drug: Magnesium
Normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Discharge pain medication given to all patients
Study: NCT05488847
Drug: Oxycodone Hydrochloride 5 Mg
Normalized name: oxycodone hydrochloride 5 MG
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Only given to active comparator group
Study: NCT06316960
Drug: Avapritinib
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50mg/m2/day for weighing bodyweight \>10kg, 1.65mg/kg/day for weighing ≤ 10kg, po, qd, d1-28.
Study: NCT05764161
Drug: Ruxolitinib Cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.
Study: NCT05671991
Drug: Empagliflozin 25 mg vs Placebo
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Acute Study- Empagliflozin 25 mg vs Placebo on D1 then alternate therapy on D7
Study: NCT06316960
Drug: Azacitidine Injection
Normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 75mg/m2/d for weighing \>10kg, 2.5mg/kg/d for weighing ≤ 10kg, d1-7, ivgtt, qd, more than 3 hours. Azacitidine and decitabine cannot be used simultaneously.